This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
myelofibrosis
Myelofibrosis
Myelofibrosis is a MPN with BM fibrosis, megakaryocyte dysplasia, and splenomegaly; drivers JAK2 V617F ~60%, CALR exon 9 ~20-25%, MPL ~8%; ruxolitinib (COMFORT-I/II), fedratinib, pacritinib, momelotinib (MOMENTUM) approved; allo-SCT is the only curative option.
Entry Metadata
| Field | Value |
|---|---|
| ID | myelofibrosis |
| Name | Myelofibrosis |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. · PubMed 22375971
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798. · PubMed 22375970